Aprazer Healthcare Launched TAFSURE

Aprazer Healthcare Launched TAFSURE (Tenofovir alafenamide ) is a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. It was developed by Gilead Sciences based on the protide technology of Chris McGuigan for use in the treatment of HIV/AIDS and chronic hepatitis B, and is applied in the form of tenofovir alafenamide fumarate